Prevention with a Twist: Developing MPTs with the End-User in Mind

Chastain Mann, Mann Global Health and the Initiative for MPTs; 20 March 2018
Multipurpose prevention technologies

MPTs combine protection against:

- Unintended pregnancy
- HIV
- Other STIs

The ideal MPT would be:

- Extremely safe
- Affordable
- Easy-to-use
MPTs in the development pipeline

- Vaginal rings
- Innovative vaginal delivery products
- Injectables and implant technologies
- New male and female condom designs
- Other novel technologies and platforms
Online MPT Product Development Database

Learn more at http://mpts101.org/mpt-database

MPT Product Development Database

This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Click here to learn more about the inclusion criteria and information update methodology.

Help us keep the database complete and up to date! If you know of an MPT product not included in the database or have updated information for listed products, please contact us using the “MPT Database Feedback” form.

MPT Database Feedback

Check out the MPT products in the development pipeline – view an MPT Pipeline Table by Indication Combination.
End-user research is critical: lessons learned from microbicide trials

VOICE

• None of the products tested proved to be effective among the women enrolled in the trial; most participants did not use them daily as recommended.

• “Urgent need for safe, effective and practical HIV prevention methods that young, unmarried women will actually use.”

FACTS 001

• “For most of this population of young, unmarried women, the majority of whom still live with their parents, using the gel consistently proved to be very challenging.”

• “More end-user centered research is needed to understand barriers and motivators of product use, as well as preferred methods and dosage forms.”

http://www.mtnstopshiv.org/node/2003
Recent MPT end-user work: a snapshot

• TRIO Study (RTI International)
• MPT perceptibility research (Guthrie)
• Product-specific projects (CONRAD, Population Council, IPM, PATH, etc.)
Financing for the MPT field

- Recent USG RFAs inclusive of end-user research
- Need for diversification of funding
Join the IMPT Network!

Learn more at http://mpts101.org/membership

IMPT Membership

Overview

The IMPT Network of Experts (NoE) is composed of experts working in reproductive health, STI and HIV prevention, product development or another related field. To become a member, individuals must complete an IMPT Membership form. Members may provide technical and regional expertise, on a limited and ad hoc basis, to the working groups and Steering Committee to address specific questions/issues in support of IMPT’s three priority areas: 1) the Scientific Agenda; 2) Communications and Advocacy; 3) Access, Demand and Uptake; and 4) Supporting Agency Coordination. The Network of Experts also serves to expand awareness of MPTs and investment in the IMPT.

Members of the Network of Experts have no set time commitment to the IMPT and are only asked to participate on an ad hoc/as needed basis.

Responsibilities

Members of the IMPT Network of Experts:

1. May be asked to represent the IMPT at external meetings/conferences;
2. Will participate on occasional conference calls or initiative meetings as needed;
3. Will incorporate information and messaging about MPTs into their work;
4. Agree to review documents related to their area of expertise; and
5. Agree to have their name and affiliation cited as a member of the IMPT Network of Experts.

Why we need MPTs

NEWS: Apply for NIH Next Generation Multipurpose Prevention Technologies (NGM) to support the development of
Thank you!

The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to advancing the comprehensive sexual and reproductive health of women and girls worldwide. CAMI Health is housed at the Public Health Institute (PHI).

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.